Company profile
Ticker
GUTS
Exchange
Website
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
3M • Ares Capital • Becton, Dickinson and • Stryker • Boston Scientific • Solventum • Baxter International • Teleflex • Hercules Capital • ResMed ...
Former names
Fractyl Laboratories Inc.
SEC CIK
Corporate docs
IRS number
273553477
GUTS stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Cost Associated with Exit or Disposal Activities
31 Jan 25
8-K
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study
13 Jan 25
8-K
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 Nov 24
10-Q
2024 Q3
Quarterly report
12 Nov 24
8-K
Regulation FD Disclosure
4 Nov 24
8-K
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
8-K
Regulation FD Disclosure
30 Jul 24
8-K
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
24 Jun 24
10-Q
2024 Q1
Quarterly report
13 May 24
Latest ownership filings
SC 13G
BVP VII SPECIAL OPPORTUNITY FUND LP
14 Feb 25
SC 13G
BlackRock, Inc.
4 Feb 25
4
Harith Rajagopalan
3 Feb 25
4
Jay David Caplan
3 Feb 25
144
Notice of proposed sale of securities
30 Jan 25
144
Notice of proposed sale of securities
30 Jan 25
SC 13G
MAVERICK CAPITAL LTD
14 Nov 24
4
Harith Rajagopalan
13 Nov 24
4
Jay David Caplan
13 Nov 24
SC 13G
Mithril LP
13 Nov 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 88.92 mm | 88.92 mm | 88.92 mm | 88.92 mm | 88.92 mm | 88.92 mm |
Cash burn (monthly) | 6.03 mm | 3.09 mm | 7.93 mm | 5.69 mm | 764.33 k | 1.56 mm |
Cash used (since last report) | 28.61 mm | 14.66 mm | 37.63 mm | 27.01 mm | 3.63 mm | 7.40 mm |
Cash remaining | 60.31 mm | 74.25 mm | 51.29 mm | 61.91 mm | 85.29 mm | 81.52 mm |
Runway (months of cash) | 10.0 | 24.0 | 6.5 | 10.9 | 111.6 | 52.3 |
Institutional ownership, Q3 2024
84.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 54 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 64.64 bn |
Total shares | 40.43 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Mithril | 5.16 mm | $17.29 mm |
General Catalyst GP V | 4.88 mm | $50.80 mm |
Deer Management | 4.77 mm | $12.07 bn |
HCC Manager | 4.67 mm | $11.82 bn |
CNVT CVF | 4.67 mm | $42.53 mm |
Maverick Capital | 4.25 mm | $10.75 bn |
BlackRock | 2.23 mm | $5.65 bn |
M28 Capital Management | 1.86 mm | $4.70 bn |
Ensign Peak Advisors | 1.41 mm | $3.56 bn |
Massachusetts Financial Services | 1.05 mm | $2.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 25 | Harith Rajagopalan | Common Stock | Sell | Dispose S | No | Yes | 1.816 | 90,972 | 165.21 k | 491,329 |
31 Jan 25 | Harith Rajagopalan | Common Stock | Option exercise | Acquire M | No | No | 1.7 | 90,972 | 154.65 k | 582,301 |
31 Jan 25 | Harith Rajagopalan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.7 | 90,972 | 154.65 k | 11,564 |
31 Jan 25 | Jay David Caplan | Common Stock | Sell | Dispose S | No | Yes | 1.8108 | 22,346 | 40.46 k | 153,544 |
31 Jan 25 | Jay David Caplan | Common Stock | Option exercise | Acquire M | No | No | 1.7 | 22,346 | 37.99 k | 175,890 |
31 Jan 25 | Jay David Caplan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.7 | 22,346 | 37.99 k | 17,924 |
30 Jan 25 | Harith Rajagopalan | Common Stock | Sell | Dispose S | No | Yes | 1.9476 | 20,948 | 40.80 k | 491,329 |
30 Jan 25 | Harith Rajagopalan | Common Stock | Option exercise | Acquire M | No | No | 1.7 | 20,948 | 35.61 k | 512,277 |
30 Jan 25 | Harith Rajagopalan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.7 | 20,948 | 35.61 k | 102,536 |
30 Jan 25 | Jay David Caplan | Common Stock | Sell | Dispose S | No | Yes | 1.9468 | 21,472 | 41.80 k | 153,544 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
1w ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
1w ago
Morgan Stanley Maintains Overweight on Fractyl Health, Lowers Price Target to $10
2w ago
Fractyl Health Announces Focus On Weight Maintenance Post-GLP-1 In REMAIN-1 Study; Midpoint Data In Q2 2025; First-In-Human Gene Therapy Study In H1 2025; Cash Runway Extended To 2026
2w ago
Fractyl Health Reports Initial Results Showing Sustained Weight Maintenance After GLP-1 Discontinuation And Revita Treatment In First REVEAL-1 Cohort Patient
1mo ago
Press releases
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
2w ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
2mo ago